Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention

Journal of Controlled Release

Volumn 199, Issue , 2015, Pages 122-131

  Kim, Ji Young ^a   Al Hilal, Taslim A ^a   Chung, Seung Woo ^a   Kim, Sang Yoon ^b,c,d   Ryu, Gyu Ha ^e   Son, Woo Chan ^c,d   Byun, Youngro ^a,f  

^a Seoul National University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Asan Medical Center   (South Korea)

^e Sungkyunkwan University   (South Korea)

^f Seoul National University   (South Korea)

Author keywords

Angiogenesis inhibitor; Chemoprevention; Heparin conjugate; Lung cancer; Oral delivery

Indexed keywords

BIOLOGICAL ORGANS; DRUG THERAPY; MAMMALS; POLYSACCHARIDES; TUMORS;

ANGIOGENESIS INHIBITORS; CHEMOPREVENTION; HEPARIN CONJUGATE; LUNG CANCER; ORAL DELIVERY;

DISEASES;

ANGIOGENESIS INHIBITOR; CD34 ANTIBODY; CD34 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; KI 67 ANTIGEN; LHTD4; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY KI 67; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; COLLAGEN; DRUG COMBINATION; FIBROBLAST GROWTH FACTOR RECEPTOR; LAMININ; MATRIGEL; PROTEOGLYCAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER SIZE; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PHARMACEUTICAL CARE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WEIGHT CHANGE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER TRANSPLANTATION; CARBOHYDRATE ANALYSIS; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; LUNG CIRCULATION; LUNG NEOPLASMS; MOLECULAR GENETICS; PHOSPHORYLATION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CARBOHYDRATE SEQUENCE; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KI-67 ANTIGEN; LAMININ; LUNG NEOPLASMS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEOGLYCANS; PULMONARY CIRCULATION; RECEPTORS, FIBROBLAST GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920457610     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.12.015     Document Type: Article

References (38)

1. T.M. Niers, C.P. Klerk, M. DiNisio, C.J. Van Noorden, H.R. Buller, and P.H. Reitsma Mechanisms of heparin induced anti-cancer activity in experimental cancer models Crit. Rev. Oncol. Hematol. 61 2007 195 207
2. S.A. Mousa, and L.J. Petersen Anti-cancer properties of low-molecular-weight heparin: preclinical evidence Thromb. Haemost. 102 2009 258 267
3. L. Zacharski, D. Ornstein, and A. Mamourian Low-molecular-weight heparin and cancer Semin. Thromb. Hemost. 26 2000 69 77
4. K. Park, G.Y. Lee, Y.S. Kim, M. Yu, R.W. Park, and I.S. Kim Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity J. Control. Release 114 2006 300 306
5. D.Y. Lee, S.K. Kim, Y.S. Kim, D.H. Son, J.H. Nam, and I.S. Kim Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate J. Control. Release 118 2007 310 317
6. D.Y. Lee, K. Park, S.K. Kim, R.W. Park, I.C. Kwon, and S.Y. Kim Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis Clin. Cancer Res. 14 2008 2841 2849
7. E. Lee, Y.S. Kim, S.M. Bae, S.K. Kim, S. Jin, and S.W. Chung Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor Int. J. Cancer 124 2009 2755 2765
8. J.W. Park, O.C. Jeon, S.K. Kim, T.A. Al-Hilal, S.J. Jin, and H.T. Moon High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives J. Control. Release 148 2010 317 326
9. S.W. Chung, M. Lee, S.M. Bae, J. Park, O.C. Jeon, and H.S. Lee Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge Biomaterials 33 2012 9070 9079
10. F. Alam, T.A. Al-Hilal, S.W. Chung, D. Seo, F. Mahmud, and H.S. Kim Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid Biomaterials 35 2014 653 6552
11. T.A. Al-Hilal, J. Park, F. Alam, S.W. Chung, J.W. Park, and K. Kim Oligomeric bile acid-mediated oral delivery of low molecular weight heparin J. Control. Release 175 2014 17 24
12. T.A. Al-Hilal, S.W. Chung, F. Alam, J. Park, K.E. Lee, and H. Jeon Functional transformations of bile acid transporters induced by high-affinity macromolecules Sci. Rep. 4 2014 4163
13. S. Lee, J. Lee, D.Y. Lee, S.K. Kim, Y. Lee, and Y. Byun A new drug carrier, Nalpha-deoxycholyl-L: -lysyl-methylester, for enhancing insulin absorption in the intestine Diabetologia 48 2005 405 411
14. O.C. Jeon, S.R. Hwang, T.A. Al-Hilal, J.W. Park, H.T. Moon, and S. Lee Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates Pharm. Res. 30 2013 959 967
15. J.W. Park, S.R. Hwang, O.C. Jeon, H.T. Moon, and Y. Byun Enhanced oral absorption of ibandronate via complex formation with bile acid derivative J. Pharm. Sci. 102 2013 341 346
16. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
17. A. Albini, F. Tosetti, V.W. Li, D.M. Noonan, and W.W. Li Cancer prevention by targeting angiogenesis. Nature reviews Clin. Oncol. 9 2012 498 509
18. A. Albini, D.M. Noonan, and N. Ferrari Molecular pathways for cancer angioprevention Clin. Cancer Res. 13 2007 4320 4325
19. G. Bergers, and L.E. Benjamin Tumorigenesis and the angiogenic switch Nat. Rev. Cancer 3 2003 401 410
20. A. Albini, and M.B. Sporn The tumour microenvironment as a target for chemoprevention Nat. Rev. Cancer 7 2007 139 147
21. E.H. Blackburn Cancer interception Cancer Prev. Res. (Phila.) 4 2011 787 792
22. M.B. Sporn, and D.L. Newton Chemoprevention of cancer with retinoids Fed. Proc. 38 1979 2528 2534
23. C. Gerhauser Cancer chemoprevention and nutri-epigenetics: state of the art and future challenges Top. Curr. Chem. 2012
24. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J. Clin. 63 2013 11 30
25. L. Tong, M.R. Spitz, J.J. Fueger, and C.A. Amos Lung carcinoma in former smokers Cancer 78 1996 1004 1010
26. R.S. Herbst, A. Onn, and A. Sandler Angiogenesis and lung cancer: prognostic and therapeutic implications J. Clin. Oncol. 23 2005 3243 3256
27. V. Karoor, M. Le, D. Merrick, E.C. Dempsey, and Y.E. Miller Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors Cancer Prev. Res. (Phila.) 3 2010 1141 1147
28. R.L. Keith, Y.E. Miller, R.M. Gemmill, H.A. Drabkin, E.C. Dempsey, and T.C. Kennedy Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer Clin. Cancer Res. 6 2000 1616 1625
29. S.R. Hwang, D.H. Seo, T.A. Al-Hilal, O.C. Jeon, J.H. Kang, and S.H. Kim Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis J. Control. Release 163 2012 374 384
30. H. Orita, J. Coulter, E. Tully, F.P. Kuhajda, and E. Gabrielson Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors Clin. Cancer Res. 14 2008 2458 2464
31. O.C. Jeon, S.R. Hwang, T.A. Al-Hilal, J.W. Park, H.T. Moon, and S. Lee Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates Pharm. Res. 30 2013 959 967
32. C.L. Morton, and P.J. Houghton Establishment of human tumor xenografts in immunodeficient mice Nat. Protoc. 2 2007 247 250
33. P. Carmeliet, and R.K. Jain Molecular mechanisms and clinical applications of angiogenesis Nature 473 2011 298 307
34. A.S. Chung, J. Lee, and N. Ferrara Targeting the tumour vasculature: insights from physiological angiogenesis Nat. Rev. Cancer 10 2010 505 514
35. A.Y. Nikitin, A. Alcaraz, M.R. Anver, R.T. Bronson, R.D. Cardiff, and D. Dixon Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium Cancer Res. 64 2004 2307 2316
36. M. Relf, S. LeJeune, P.A. Scott, S. Fox, K. Smith, and R. Leek Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res. 57 1997 963 969
37. J.-y. Kim, F. Alam, S.W. Chung, J. Park, O.C. Jeon, and S.Y. Kim Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice Anti-Cancer Drugs 2014
38. J.B. Johnston, S. Navaratnam, M.W. Pitz, J.M. Maniate, E. Wiechec, and H. Baust Targeting the EGFR pathway for cancer therapy Curr. Med. Chem. 13 2006 3483 3492